3 recruiting, 2 terminated, 1 active not recruiting. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 3, Terminated 2, Active not recruiting 1 |
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
Follow Advanced Lung Carcinoma: new trials by email Literature Review of Advanced Lung Carcinoma trials Research Report on Advanced Lung Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BBO-11818 in Adult Subjects With KRAS Mutant Cancer BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin) - Non-Small Cell Lung Cancer, NSCLC | Phase 1 | Recruiting | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 665 | 2025-03-31 | 2026-06-02 |
| Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer BBO-8520, Pembrolizumab, BBO-10203 - Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer | Phase 1 | Recruiting | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 350 | 2024-05-22 | 2026-09-03 |
| Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations silevertinib monotherapy - Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer | Phase 1 / Phase 2 | Recruiting | Black Diamond Therapeutics, Inc. | 220 | 2022-03-31 | 2026-11-18 |
| A Study to Investigate LYL797 in Adults With Solid Tumors LYL797 - Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 1 | Terminated | Lyell Immunopharma, Inc. | 57 | 2022-03-29 | 2025-07-01 |
| Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies Anti-CTLA4 Monoclonal Antibody BMS-986218, Nivolumab, Stereotactic Body Radiation Therapy - Advanced Lung Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 13 | 2021-03-29 | 2026-03-03 |
| Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Brigatinib, Local Consolidation Therapy - Advanced Lung Carcinoma, ALK Gene Rearrangement | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2018-12-18 | 2026-11-10 |
Carcinoma, Non-Small-Cell Lung (5) · Lung Neoplasms (5) · Neoplasm Metastasis (3) · Adrenal Gland Neoplasms (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Ovarian Epithelial (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Liver Neoplasms (1) · Ovarian Neoplasms (1) · Recurrence (1) · Triple Negative Breast Neoplasms (1)
Lung Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Respiratory Tract Diseases (6) · Respiratory Tract Neoplasms (6) · Thoracic Neoplasms (6) · Bronchial Neoplasms (5) · Carcinoma, Bronchogenic (5) · Neoplastic Processes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Carcinoma (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2)
pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Carboplatin (1) · Cetuximab (1) · Cisplatin (1) · Gemcitabine (1) · Nivolumab (1) · Pemetrexed (1) · Radiosurgery (1) · brigatinib (1)
M.D. Anderson Cancer Center (2) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) (2) · Black Diamond Therapeutics, Inc. (1) · Lyell Immunopharma, Inc. (1)
United States (6) · Australia (2) · Canada (2) · Denmark (1) · Spain (1)
Jackie Walling, MBChB, PhD (1) · James Welsh (1) · Yasir Y Elamin, MD (1)